PETRI DISH PERSPECTIVES

Episode 80: Dr. Meesha Dogan on Using AI and Epigenetics to Detect Heart Disease Early

Send us Fan Mail After a two-generation family history of heart disease, Dr. Meesha Dogan set out to change how the disease is detected. As founder and CEO of Cardio Diagnostics, she built and commercialized what the company describes as the first epigenetics-based clinical test for heart disease driven by AI, then took the company public on Nasdaq in 2022. Since then, it has earned a dedicated AMA CPT code for its PrecisionCHD test, won a Vizient innovative technology contract, and launched its first international partnership in India. In this episode, Dr. Dogan unpacks why roughly 80% of cardiovascular events are preventable yet still so often missed, how combining genetics and epigenetics gives a fuller picture of heart disease risk, and what it takes to move a diagnostic from the lab to reimbursement, health systems, and employers. Check out Cardio Diagnostics: https://www.cdio.ai/ 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Cardiology #HeartHealth #Epigenetics #AIinHealthcare #PrecisionMedicine #Diagnostics #Biotech #HealthTech #PreventiveMedicine #WomenInSTEM #CardioDiagnostics Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

October 2026: Biotech & Pharma NEWS Roundup

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for October 2026! This month was defined by a wave of oncology approvals, a head-to-head data drop that reshuffled the GLP-1 race, and M&A activity that shows Big Pharma is quietly pivoting away from oncology toward rare disease, pain, and RNA therapeutics. The FDA approved dostarlimab in locally advanced rectal cancer, tucatinib in HER2-positive breast cancer, and talazoparib plus enzalutamide in metastatic prostate cancer — three meaningful wins for patients in a single month. Lilly’s retatrutide beat Ozempic head-to-head with 20.9% weight loss in diabetic patients, cementing its status as the next major GLP-1 contender. On the deal front, Shionogi paid $2 billion for IntraBio in rare neurodegeneration, Viatris acquired Pacira BioSciences for $1.65 billion in non-opioid pain, and Merck KGaA bought Silence Therapeutics at a 130% premium — six deals totaling over $7 billion for the month. VC finished strong with Formation Bio raising $600 million to buy drug candidates and Dren Bio closing $350 million, part of over $1.4 billion in rounds in the final week alone. And HHS greenlighted six experimental peptides over the open objections of FDA career scientists — a regulatory move that signals growing tension between evidence standards and the current policy posture. The bigger story: capital is flowing, but it’s getting selective — and the therapeutic areas winning M&A attention this month tell you exactly where the smart money thinks the next decade of returns will come from. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 79: Endeavor Health

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Endeavor Health, the Chicago-area hospital system most Illinoisans have driven past but couldn’t name. Born from Evanston Hospital in 1891, grown into NorthShore University HealthSystem, expanded through a 2022 merger with Edward-Elmhurst Health, and rebranded as Endeavor Health in December 2023, this is a system that has been quietly becoming one of the largest in the state. We break down Endeavor’s origins, its nine-hospital suburban footprint, the NorthShore Research Institute, and the financial reality of running a $6.4 billion system at near-zero operating margin and why that made what happened next almost inevitable. On October 14th, 2026, Endeavor and Rush University System for Health announced a proposed merger that would create a $10 billion combined system with 12 hospitals, 400+ care sites, 46,000 employees and clinicians, and over 2 million patients a year. We get into the deal mechanics, the leadership shake-up, the $1 billion endowment investment, and what nurses, patients, and healthcare economists are already pushing back on. This is a story about scale, survival, and what happens when a fragmented market finally stops pretending consolidation isn’t coming. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #EndeavorHealth #Rush #ChicagoHealthcare #HospitalMerger #HealthcareConsolidation #NorthShore #EdwardElmhurst #RushUniversity #HealthPolicy #HealthcareNews #LifeSciences #Healthcare #HealthcareLeadership #BiotechNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 78: Dr. Kristin Gleitsman on Using AI to Make Better Drug Development Decisions

Send us Fan Mail After years of building discovery engines inside diagnostics, Kristin Gleitsman has become one of the more skeptical voices in AI and biology. A Caltech chemistry PhD, Kristin built Veracyte’s Discovery Research function from the ground up and helped shape the strategy behind its acquisition of C2i Genomics. Now, as Chief Science Officer of Eigen Bio, the focus is on a harder question than building bigger models: what has an AI model actually earned the right to claim? In this episode, Kristin unpacks why more data layers don’t automatically mean more biological truth, how better mechanistic evidence could change drug development decisions, and what it takes to hold AI-bio claims, including your own company’s, to a higher standard. Kristin also shares lessons from the weekly AI∩Bio newsletter on separating real progress from hype. Check out Eigen Bio: https://eigenbioai.com/ Read AI∩Bio: Reading the Revolution: https://kristinrulegleitsman.com/ai-∩-bio/ 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #AIinBiotech #DrugDiscovery #PrecisionMedicine #Diagnostics #Multiomics #Biotech #HealthTech #Oncology #AIBio #EigenBio Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

Episode 77: Revolution Medicines

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Revolution Medicines, the precision oncology company that spent over a decade trying to drug one of cancer’s most notorious targets: RAS. With mutations present in roughly 30% of all new cancer diagnoses, including pancreatic, lung, and colorectal cancers, RAS has long been considered undruggable. Revolution bet their entire company on proving that wrong. We break down the science behind their tricomplex inhibitor platform, the three lead drugs in their pipeline, daraxonrasib, elironrasib, and zoldonrasib, and the landmark Phase 3 RASolute 302 results that showed unprecedented overall survival in metastatic pancreatic cancer, earned a Plenary presentation at ASCO 2026, and triggered an FDA NDA review. But this is also a story about the pressure of building an ambitious company with no revenue, nearly $1 billion in annual R&D spend, and a failed $30 billion acquisition attempt with Merck that sent the stock crashing 26% in a single day. Revolution walked away from the deal. The question now is whether that confidence was prescient or premature. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #RevolutionMedicines #RAS #KRAS #Oncology #PancreaticCancer #LungCancer #Daraxonrasib #Biotech #DrugDiscovery #PrecisionOncology #CancerResearch #FDA #LifeSciences #Healthcare #BiotechTok #BiotechNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 76: Dr. Avinash Jayaraman on Why Your Kid's Screen Time Is a Clinical Emergency

Send us Fan Mail After training as a physician, earning an MBA from Wharton, and co-founding Sonara Health, a digital health company that raised over $10 million from the NIH, VCs, Dr. Avinash Jayaraman could have gone in almost any direction. He chose to focus on one of the most urgent and underserved crises in adolescent health: the mental health epidemic driven by technology overuse. In this episode, Dr. Jayaraman unpacks why screen time and social media have become a clinical problem, not just a parenting debate, what it actually takes to build a mental health startup for kids and teens in a system that has historically ignored them, and why he believes the solution has to combine real clinical care with a deep understanding of how technology rewires the adolescent brain. Check out Blue Light Health: https://bluelighthealth.com/ 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BlueLightHealth #MentalHealth #AdolescentHealth #DigitalHealth #TechAddiction #ScreenTime #HealthTech #Startups #Healthcare #BiotechTok Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

September 2026: Biotech & Pharma NEWS Roundup

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for September 2026! This month was defined by blockbuster dealmaking, historic FDA approvals, and a growing recognition that pharmaceutical innovation is shifting east. AstraZeneca made a $2 billion strategic bet on Summit Therapeutics and its ivonescimab program, Novo Nordisk paid up to $2.6 billion for a once-weekly oral GLP-1 from China's Hengrui, and Eli Lilly continued its relentless dealmaking streak with a $3.25 billion InnoCare partnership. On the regulatory front, the FDA approved the first-ever treatment for Sanfilippo syndrome, a first-in-class Parkinson's drug, the world's first radioligand equivalent, and a new once-weekly insulin, a remarkable month for patients with rare and chronic diseases. ADARx raised $446 million in one of biotech's largest IPOs of the year, and Electra Therapeutics upsized its own raise to $350 million, signaling that the IPO window remains open for the right science. Meanwhile, Novo's total workforce cuts reached 13,000 and BMS continued trimming headcount, a reminder that even the industry's biggest players are restructuring for what comes next. The bigger story is unmistakable: China is no longer just manufacturing drugs for the West, it is discovering them, and the deals signed this month prove that Big Pharma has fully accepted that reality. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 75: Hengrui

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Jiangsu Hengrui Pharmaceuticals, the Chinese pharma giant that started as a state-owned generic drug factory in 1970 and quietly became one of the most important drug companies in the world. Over $15 billion in deals with GSK and Novo Nordisk. The world's top clinical trial sponsor. One of the top five drug pipelines globally. All from a city most people can't find on a map. We break down how Hengrui made the pivot from generics to innovation, why Western pharma is now writing billion-dollar checks for Chinese science, and the controversies, including a scathing FDA warning letter and corruption scandals, that complicate the story. Because Hengrui wasn't hiding. It was building, the whole time. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Hengrui #ChinaBiotech #Pharma #Biotech #DrugDiscovery #NovoNordisk #GSK #GLP1 #Oncology #LifeSciences #Healthcare #BiotechInnovation #PharmaceuticalIndustry Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 74: Dr. John Murphy on Building an Audience

Send us Fan Mail After years of running a school on the rigid rhythm of bells, Dr. John Murphy walked away from K-12 education and into something he never trained for: performing history at bars. In this episode, John unpacks how a credentialed academic builds an audience outside the walls of a traditional institution, why humor and analogies are the secret weapons of great storytelling, and what it actually takes to turn expertise into something people will pay a bar tab to hear. Quick note: this one's a bit of a departure from our usual biotech and pharma coverage, but the story was too good to pass up. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #Edutainment #ScienceCommunication #ContentCreator #PersonalBrand #PublicSpeaking #HistoryLecture #Storytelling #ChicagoEvents #CreatorEconomy Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

Episode 73: Anew Labs

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Anew Labs, the AI drug discovery company that emerged from one of the most unexpected places in biotech: ByteDance, the parent company of TikTok. Fresh off a $290 million raise at a $1.5 billion valuation, Anew is betting that artificial intelligence can fundamentally change how we discover medicines, not by making existing drug development slightly faster, but by rethinking the entire discovery process from the ground up. We'll break down why ByteDance got into drug discovery in the first place, how Anew's AI platforms work across protein structure prediction, molecular design, and antibody optimization, and what makes its first-in-class small molecule IL-17 program one of the most scientifically ambitious bets in the company's pipeline. We'll also explore the broader competitive landscape, from Anthropic's $400 million acquisition of Coefficient Bio to NVIDIA and Eli Lilly's $1 billion co-innovation lab and what it means that Big Tech is no longer just building tools for pharma, but trying to become the drug company itself. But the biggest question hanging over all of it remains unanswered: can AI actually discover drugs? Not molecules that look promising on a computer. A medicine that works in humans, survives clinical development, gets approved, and changes patient outcomes. We'll dig into why the proof hasn't arrived yet and why Anew is one of the most important tests of that question in the world right now. Because the next breakthrough in medicine may not come from a traditional pharmaceutical company. It may come from an algorithm trained on biology and a team willing to bet everything that the computer got it right. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #AnewLabs #AIDrugDiscovery #ByteDance #Biotech #Biotechnology #Pharma #ArtificialIntelligence #DrugDiscovery #MachineLearning #LifeSciences #Healthcare #Isomorphic #Anthropic #NVIDIA #EliLilly #BispecificAntibody #Immunology #AIinHealthcare #BiotechInnovation #PrecisionMedicine #DrugDevelopment Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 72: Dr. Elliot Justin on S3xual Wearable Health Tech

Send us Fan Mail After a career spent racing against the clock in emergency rooms, Dr. Elliot Justin found himself chasing a very different kind of vital sign, one most men never think to track. Before FirmTech, he built and exited a telemedicine company and a physician staffing group. But it's the wearable ring, designed to quietly monitor erectile function, that's turning heads for an unexpected reason: the data may predict cardiovascular risk years before symptoms ever show up. In this episode, Dr. Justin unpacks how a symptom most men are taught to ignore became one of the most promising early-warning signals in preventive cardiology and what it actually takes to build a hardware company in one of medicine's most stigmatized categories. Check out FirmTech: https://myfirmtech.com/ Use MANEAD15 to receive a discount on FirmTech products. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #HealthTech #DigitalHealth #WearableTech #CardiovascularHealth #MensHealth #PreventiveMedicine #Biotech #HealthInnovation #StartupFounder #MedTech #FirmTech Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

Episode 71: Fate of Pharma M&A

Send us Fan Mail In this episode of Petri Dish Perspectives, we take a step back from individual companies to examine one of the most powerful forces shaping the pharmaceutical industry: M&A, licensing, and the global competition for innovation. We explore how today's pharmaceutical giants were built through decades of consolidation, from Pfizer, GlaxoSmithKline, and Novartis to some of the industry's biggest modern transactions and why dealmaking has increasingly become essential for companies facing massive patent cliffs. But modern pharma is changing. Instead of relying solely on internal R&D or pursuing enormous megamergers, companies are increasingly acquiring targeted biotechs, licensing individual assets, and looking outside traditional innovation hubs for their next blockbuster. We'll also dive into one of the biggest shifts happening in biotech today: the rise of China and Asia as sources of innovative drug development. Western pharmaceutical companies are increasingly licensing molecules and technologies developed outside the U.S. and Europe, even as governments push for supply-chain independence and greater scrutiny of strategic relationships with China. What happens when the pharmaceutical industry is becoming more global while geopolitics is becoming less global? From the biggest deals in pharmaceutical history to the future of cross-border biotech partnerships, this episode asks a bigger question: Has Big Pharma become too dependent on buying innovation rather than building it? And if the best science can increasingly come from anywhere in the world, who will ultimately control the future of medicine? Because pharmaceutical M&A isn't just about buying companies. It's about deciding who gets to own the future of medicine. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #Pharma #Biotech #PharmaMA #BiotechMA #DrugDevelopment #BigPharma #PharmaceuticalIndustry #BiotechInnovation #Healthcare #LifeSciences #BusinessDevelopment #Licensing #PatentCliff #ChinaBiotech #GlobalHealth #Geopolitics #DrugDiscovery #Innovation #HealthcareInnovation Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

August 2026: Biotech & Pharma NEWS Roundup

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for August 2026! This month was defined by major dealmaking, a resurgence in biotech financing, and growing questions about where the global biotech industry is headed. Roche made a $2.5 billion bet on Hanmi, McKesson acquired Precision Medicine Group for $2.25 billion, and the investors behind Metsera quickly returned with Sentivera and a licensing deal worth up to $1.5 billion. Meanwhile, companies including Apnimed, Attovia, and Braveheart kept the IPO market active, suggesting that investor appetite for biotech may be continuing to recover. On the regulatory front, a series of FDA approvals expanded treatment options across HIV, autoimmune disease, cardiovascular disease, cancer, and rare disorders, while three reported deaths in Chinese gene therapy trials sparked renewed debate in Washington about clinical-trial oversight and the FDA's reliance on international data. The bigger story is clear: biotech is becoming increasingly global, capital-intensive, and interconnected, where success depends not only on great science, but also on manufacturing, financing, regulation, and strategic partnerships. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 70: Cellares

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Cellares, the biotech company trying to solve one of the biggest and least discussed challenges in cell therapy: how do you manufacture these complex, personalized medicines at commercial scale? From CAR-T to gene-edited cell therapies, the science may be advancing rapidly, but manufacturing remains labor-intensive, expensive, and difficult to scale. Cellares believes the answer is automation. We’ll break down the origins of Cellares, the engineering philosophy behind its Cell Shuttle platform, and how the company is attempting to turn cell therapy manufacturing into something closer to an automated pharmaceutical factory. We’ll also explore its partnerships with companies including Bristol Myers Squibb and Cabaletta Bio, the massive investment behind its Smart Factory network, and why pharmaceutical companies have become increasingly interested in automating cell therapy production. But there’s a major twist: Bristol Myers Squibb recently terminated its partnership with Cellares, raising questions about whether the Cell Shuttle is truly ready for commercial-scale manufacturing. We’ll unpack what happened, why manufacturing a clinical-stage therapy isn't necessarily the same as manufacturing a commercial product, and what this could mean for Cellares and the broader future of automated cell therapy. Because the next breakthrough in cell therapy may not be another drug, it may be the factory that finally makes these living medicines scalable. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Cellares #CellTherapy #CAR_T #CAR-T #Biotech #Biotechnology #Pharma #CellTherapyManufacturing #Biomanufacturing #GeneTherapy #DrugDevelopment #LifeSciences #Healthcare #BristolMyersSquibb #CabalettaBio #CellShuttle #Manufacturing #BiotechInnovation #PrecisionMedicine Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 69: Summit Therapeutics

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the remarkable rise of Summit Therapeutics, a biotech that transformed itself from an infectious-disease company into one of the most closely watched oncology companies in the world. At the center of the story is ivonescimab, a next-generation bispecific antibody targeting both PD-1 and VEGF and a drug that could potentially challenge Merck’s blockbuster Keytruda. We’ll dive into Summit’s origins, the company’s dramatic pivot, the story behind its partnership with China’s Akeso, and the science behind why combining immune checkpoint inhibition with VEGF blockade could create a powerful new approach to cancer treatment. We’ll also break down the clinical data in lung cancer, Summit’s growing pipeline, the massive commercial opportunity, and the risks surrounding regulatory approval, clinical durability, and the company’s heavy dependence on a single lead asset. But Summit’s story goes far beyond one cancer drug. Ivonescimab represents a broader shift in how medicines are discovered and commercialized, with innovative assets increasingly emerging from Chinese biotech and being licensed by Western companies for global development. Could Summit become the company that brings a new generation of cancer therapeutics to the world and could ivonescimab really become a challenger to Keytruda? 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #SummitTherapeutics #Ivonescimab #Biotech #Biotechnology #Pharma #Oncology #Cancer #CancerResearch #Immunotherapy #BispecificAntibodies #PrecisionMedicine #DrugDevelopment #ClinicalTrials #Keytruda #Merck #ChineseBiotech #Healthcare #LifeSciences #PharmaceuticalIndustry Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 68: Guardant Health

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Guardant Health, one of the companies leading the shift toward blood-based cancer detection and precision oncology. Founded by genomic scientists Helmy Eltoukhy and AmirAli Talasaz, Guardant is betting that a simple blood draw can reveal critical information about the biology of a tumor, from identifying mutations and guiding treatment to monitoring residual disease and potentially detecting cancer earlier. We'll dive into the science behind liquid biopsy and circulating tumor DNA, Guardant's evolution from Guardant360 into a broader precision-oncology platform, the rise of its Shield colorectal cancer screening test, and the company's growing role in pharmaceutical drug development, real-world evidence, and AI. We'll also explore the promise and major challenges of multi-cancer early detection, including the questions around sensitivity, false positives, reimbursement, and whether detecting cancer earlier actually translates into better outcomes. Because the future of cancer care may not just be about developing better treatments, but about being able to continuously read what cancer is doing inside the body from something as simple as a blood sample. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #GuardantHealth #LiquidBiopsy #Cancer #Oncology #Biotech #Healthcare #PrecisionMedicine #CancerDetection #Genomics #ctDNA #Diagnostics #HealthTech #Pharma #AI #Biotechnology #FutureOfHealthcare Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 67: Epic Systems

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Epic Systems, the privately held healthcare technology company that has quietly built much of the digital infrastructure behind American healthcare. From Judy Faulkner founding Epic in a Wisconsin basement to becoming the dominant electronic health record platform, Epic has transformed how hospitals, physicians, and patients interact with medical information. We'll dive into Epic's founding story, the evolution of its electronic health record, the rise of MyChart and Cosmos, and how Epic built a massive competitive moat through interoperability, data, workflow integration, and switching costs. We'll also explore its growing role in artificial intelligence, how Epic is embedding AI directly into clinical workflows, and the battle with companies like Oracle Health to control the future of healthcare data. Because the next generation of healthcare won't just be about developing better drugs and devices, it will be about who controls the information infrastructure connecting patients, providers, data, and AI. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #EpicSystems #Healthcare #HealthTech #Biotech #Pharma #AI #ArtificialIntelligence #DigitalHealth #HealthcareInnovation #JudyFaulkner #EHR #HealthData #MedTech #FutureOfHealthcare Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

July 2026: Biotech & Pharma NEWS Roundup

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by AI cementing itself as a core part of drug discovery, with partnerships spanning Anthropic, NVIDIA, Insilico Medicine, and major pharmaceutical companies. At the same time, billion-dollar licensing deals and acquisitions showed that large pharma is aggressively buying innovation rather than building everything internally, particularly in obesity, oncology, radiopharmaceuticals, and gene editing. Regulatory headlines—from the FTC's lawsuit against Hims & Hers to renewed debates around animal testing—reminded us that policy is evolving just as quickly as the science. And with companies like Apnimed and Scribe Therapeutics successfully entering the public markets, investor confidence appears to be returning to biotech. The takeaway is clear: the future of healthcare will be shaped by the convergence of biology, artificial intelligence, precision medicine, and strategic dealmaking—and this month may be remembered as another major step toward that future. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 66: Scribe Therapeutics

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Scribe Therapeutics, one of genome editing's most ambitious companies aiming to move beyond first-generation CRISPR. Rather than accepting the size, delivery, and precision limitations of traditional Cas9, Scribe is redesigning the molecular machinery itself, building smaller, faster, and more versatile X-Editors and pioneering the future of epigenetic regulation. We'll dive into the origins of CRISPR from bacterial immune systems to Nobel-winning breakthroughs, the protein engineering philosophy of co-founder Jennifer Doudna and Benjamin Oakes, and why pharmaceutical giants like Biogen, Eli Lilly, and Sanofi have poured resources into its platform. We'll also break down its pipeline targeting cardiometabolic diseases, rare genetic disorders, and the promise of reversible gene silencing. Because the next era of genetic medicine won't just belong to those who discover biology, but to those who engineer it into safer, more precise cures. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ScribeTherapeutics #Biotech #CRISPR #GeneEditing #ProteinEngineering #Genomics #Genetics #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Cardiometabolic #Epigenetics #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 65: Apogee Therapeutics

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Apogee Therapeutics, one of biotech's newest immunology companies aiming to redefine autoimmune disease through next-generation antibody engineering. Rather than chasing entirely new biological targets, Apogee is focused on improving what already works, developing longer-lasting biologics that could reduce injections from every few weeks to every few months. We'll dive into the evolution of modern immunology, the science behind cytokines and Fc engineering, how Apogee emerged from biotech incubator Paragon Therapeutics, and why investors have poured hundreds of millions of dollars into its vision. We'll also break down its pipeline, including APG777, APG808, and other promising candidates targeting eczema, asthma, inflammatory bowel disease, and beyond. Because sometimes the biggest innovation isn't discovering new biology, it's engineering better medicines for the patients who depend on them. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ApogeeTherapeutics #Biotech #Immunology #AutoimmuneDisease #Biologics #AntibodyEngineering #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Dermatology #Asthma #Inflammation #ProteinEngineering #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters